Mean Platelet Volume Enhances the Diagnostic Specificity of PSA for Prostate Cancer

Abstract

Mean platelet volume (MPV) is an indicator of platelet activation and has been proposed as a diagnostic marker for several kinds of cancers. We investigated the value of MPV as a diagnostic marker for prostate cancer (PCa) and examined whether MPV in combination with prostate-specific antigen (PSA) could increase the sensitivity or specificity of PSA for PCa diagnosis. For this study, 107 pathologically confirmed PCa and 177 non-PCa patients who underwent prostate biopsy were retrospectively studied. Clinical data and pre-biopsy hematological parameters were collected. The above parameters were compared between PCa and non-PCa patients. The correlation between MPV and clinical characteristics was analyzed. Receiver operating characteristic (ROC) analysis was used to explore the diagnostic value of MPV for PCa. Among all parameters analyzed, the difference was only found in MPV, platelet distribution width (PDW), and PSA between PCa and non-PCa patients. MPV was significantly decreased and PDW increased in PCa than that of non-PCa among men. ROC analysis identified MPV ≤ 9.05 fl as a cut-off value for potential PCa with area under the ROC curve (AUC) = 0.783, 95% CI = 0.733–0.833, sensitivity = 0.746, and specificity = 0.708. AUC and the sensitivity of MPV were comparable with total PSA (TPSA) or free PSA (FPSA). However, the specificity of MPV was larger than that of TPSA (0.461) or FPSA (0.561). Furthermore, MPV combined with TPSA or FPSA further enhanced the specificity of TPSA (0.844) or FPSA (0.927), but PDW did not. These findings suggested that MPV could have a predictive value for the diagnosis of PCa. MPV in combination with TPSA or FPSA could enhance the specificity of PSA and may reduce the rate of unnecessary biopsy for patients with high levels of PSA.

Causal Associations between Prostate Cancer and Various Hematological Parameters: Insights from Multivariable and Bidirectional Mendelian Randomization Analyses

“…Furthermore, Yu Z et al identi ed a link between elevated platelet counts and poorer prognoses in PCa, adding another layer to the complex relationship between hematological markers and cancer outcomes (Yu et al 2023). Complementing these ndings, Song W et al reported that integrating platelet distribution width with total or free prostate-speci c antigen levels could re ne the diagnostic precision for PCa, enhancing the clinical value of PSA testing (Song et al 2022). Despite these insightful correlations, our study did not replicate these associations, potentially highlighting the in uence of confounding variables and the intricate dynamics governing the interaction between hematological markers and PCa.…”

Technetium-99m-methylene diphosphonate single photon emission computed tomography/computed tomography combined with prostate-specific antigen/free prostate-specific antigen ratio for bone metastasis of prostate cancer

“…Inclusion criteria of Exp group were: (1) Patient age ≥ 18 years; (2) patients with no recent history of trauma or surgery; (3) patients who met the clinical diagnostic criteria of PC[ 11 ]; (4) patients who did not receive chemoradiotherapy drugs or hormone drugs; (5) patients and their families who provided written informed consent; (6) patients with complete clinical and imaging data; and (7) 99mTc-MDP SPECT/CT imaging and serum PSA/fPSA detection that could be accepted.…”

Platelet detection as a new liquid biopsy tool for human cancers

“…The increase of MPV as a marker has also been observed in patients with CRC ( 55 ), metastatic CRC ( 56 ), gastric cancer ( 57 ), papillary thyroid cancer ( 58 , 59 ), pancreatic cancer ( 60 ), and oral cancer ( 61 ). Interestingly, no change of or decreased MPV was also observed between cancer patients and healthy subjects in the studies of CRC ( 62 ), lung cancer ( 63 , 64 ), uterine cervix ( 65 ), RCC ( 66 ), oral cancer ( 67 ), and prostate cancer ( 68 ).…”